Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) EBT (2019 - 2025)

Bioadaptives' EBT history spans 7 years, with the latest figure at -$379502.0 for Q3 2025.

  • For Q3 2025, EBT fell 908.0% year-over-year to -$379502.0; the TTM value through Sep 2025 reached -$1.2 million, down 411.34%, while the annual FY2024 figure was -$694068.0, 155.19% down from the prior year.
  • EBT for Q3 2025 was -$379502.0 at Bioadaptives, down from -$157914.0 in the prior quarter.
  • Across five years, EBT topped out at $19095.0 in Q4 2023 and bottomed at -$491903.0 in Q1 2021.
  • The 5-year median for EBT is -$138754.0 (2022), against an average of -$189626.6.
  • The largest annual shift saw EBT skyrocketed 116.34% in 2023 before it crashed 2196.72% in 2024.
  • A 5-year view of EBT shows it stood at -$89602.0 in 2021, then plummeted by 30.41% to -$116851.0 in 2022, then surged by 116.34% to $19095.0 in 2023, then plummeted by 2196.72% to -$400369.0 in 2024, then increased by 5.21% to -$379502.0 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's EBT are -$379502.0 (Q3 2025), -$157914.0 (Q2 2025), and -$258478.0 (Q1 2025).